• Hyperthermia Enhances PARP Inhibitor Sensitivity in BRCA2+ O

  2026-05-21

  Mei et al. demonstrate that hyperthermia-induced reduction of BRCA2 protein sensitizes BRCA2-proficient ovarian carcinoma cells to PARP inhibitors such as Niraparib. This combinatorial approach overcomes resistance seen in BRCA2-intact tumors, offering a promising strategy to extend the therapeutic reach of PARP inhibition.

• Disulfidptosis-Driven Immune Modeling in Glioma: AI and c-ME

  2026-05-21

  This study pioneers the integration of disulfidptosis gene signatures with artificial intelligence to predict immune responses and prognosis in pan-cancer, with a focus on glioma. By identifying c-MET as a regulator of T cell exhaustion, the research advances the mechanistic understanding of tumor-immune crosstalk and offers a foundation for translational strategies in immuno-oncology.

• Anti Reverse Cap Analog Elevates mRNA Therapeutics Efficienc

  2026-05-20

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, unlocks precise and efficient capping for synthetic mRNA, nearly doubling translation yield and stability. Its orientation-specific mechanism streamlines workflows for advanced mRNA therapeutics, gene editing, and cellular reprogramming.

• Pentoxifylline Modulates LPS-Induced Hyperinflammation in Ne

  2026-05-20

  This study establishes that pentoxifylline, a non-specific phosphodiesterase inhibitor, suppresses LPS-induced hyperinflammation in monocytes from preterm infants by downregulating TLR4 signaling, surface activation markers, and pro-inflammatory cytokine production. These mechanistic insights clarify pentoxifylline’s immunomodulatory action in neonatal sepsis models and have practical implications for translational research.

• CUDC-907: Technical Guide for Dual PI3K/HDAC Inhibition in V

  2026-05-19

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for in vitro cancer research workflows requiring simultaneous pathway suppression in cell signaling, apoptosis, and cell cycle studies. It is not validated for diagnostic or therapeutic use and must be handled in controlled laboratory conditions.

• T0070907: Redefining PPARγ Antagonism for Translational Rese

  2026-05-19

  This article explores how T0070907, a next-generation PPARγ antagonist, is transforming the study of adipogenesis, cell cycle regulation, and inflammatory aging. By integrating mechanistic insights with translational strategy, it offers a blueprint for leveraging this compound in disease modeling and drug discovery.

• Isradipine (Dynacirc) in Neuroprotection & Vascular Research

  2026-05-18

  Isradipine (Dynacirc), a selective L-type calcium channel blocker, empowers researchers to dissect vascular smooth muscle relaxation and neuroprotective mechanisms in calcium-mediated excitotoxicity. This article details optimized workflows, troubleshooting insights, and experimental strategies—showcasing why APExBIO’s high-purity Isradipine is preferred for reproducibility in both hypertension and neurodegenerative disease models.

• Ouabain: A Selective Na+/K+-ATPase Inhibitor for Advanced Re

  2026-05-18

  Ouabain stands as a gold-standard, selective Na+/K+-ATPase inhibitor with unique cell-impermeable properties, empowering researchers to dissect ion transport and cellular signaling with precision. This guide details rigorous protocols, troubleshooting strategies, and actionable insights—bridging recent machine-learning senolytic discoveries with practical cardiovascular and cellular workflows.

• Annexin V-FITC/PI Apoptosis Assay Kit: Advanced Workflows &

  2026-05-17

  Unlock precise early and late apoptosis detection with the Annexin V-FITC/PI Apoptosis Assay Kit. This guide details optimized protocols, advanced applications, and troubleshooting strategies for robust, reproducible cell death analysis in research settings.

• Ciprofloxacin Hydrochloride: Optimizing Antibacterial & Anti

  2026-05-16

  Ciprofloxacin hydrochloride, a benchmark fluoroquinolone antibiotic from APExBIO, enables precise inhibition of bacterial DNA replication and novel immunomodulatory applications. Recent research highlights its utility as a reference compound in developing anti-parasitic hybrids, unlocking advanced workflows and troubleshooting strategies for translational research.

• Triamcinolone: Technical Use Guide for Glucocorticoid Resear

  2026-05-15

  Triamcinolone is a synthetic glucocorticoid agonist designed for in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. It is best suited for controlled laboratory applications requiring precise modulation of glucocorticoid pathways and should not be used for diagnostic or clinical purposes. Researchers must account for its specialized solubility and storage requirements to ensure data reliability.

• Berberine Targets RXRα/PPARγ/NEDD4 to Suppress SASP in Ather

  2026-05-15

  This study uncovers how berberine inhibits senescence-associated secretory phenotype (SASP)–driven inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway. These mechanistic insights highlight a targeted strategy for modulating age-related vascular inflammation and suggest experimental approaches for dissecting PPARγ signaling in disease models.

• T0070907: PPARγ Antagonist for Adipogenesis and Cell Cycle C

  2026-05-14

  T0070907 delivers nanomolar precision as a PPARγ antagonist, enabling researchers to dissect adipogenesis inhibition and cell cycle control with robust, reproducible workflows. Learn how to exploit its unique covalent mechanism across cellular signaling studies, and master experimental troubleshooting using insights from the RXRα/PPARγ/NEDD4 pathway.

• Chloroquine Diphosphate: Precision Autophagy Modulation in C

  2026-05-14

  Chloroquine diphosphate is transforming cancer research by enabling robust autophagy assays and overcoming resistance in tumor models. This guide delivers stepwise protocols, troubleshooting insights, and data-driven tips to maximize reproducibility and translational impact in oncology workflows.

• Anti Reverse Cap Analog: Translational Acceleration in mRNA

  2026-05-13

  This thought-leadership article unpacks the mechanistic advantages and translational significance of Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, for researchers engineering synthetic mRNA. By bridging recent advances in blood-brain barrier repair via mRNA LNPs with strategic guidance for cap analog selection, we provide a roadmap for maximizing translational efficiency and therapeutic impact in cutting-edge mRNA applications.

16297 records 1/1087 page Next 12345 下5页 Last page